MSOS ETF Declines -25% Over 30 Days on Cannabis Rescheduling Pause
Key Takeaways
- MSOS declined roughly 25% over the past 30 days, retreating from a multi-month high near $5.40 to about $3.91.
- The slide was triggered by a pause in the federal process to reschedule cannabis from Schedule I to Schedule III, reviving uncertainty around Section 280E tax relief.
- The fund's concentrated, swap-based exposure to U.S. multi-state operators (MSOs) amplified the move as major holdings sold off in tandem.
- Over the trailing quarter, MSOS is down roughly 8%, reflecting a volatile, headline-driven trading range rather than a one-way trend.
- The ETF's largest exposures—Trulieve, Curaleaf, and Green Thumb Industries—remain highly sensitive to federal cannabis policy developments.
MSOS ETF Overview and Its Core Holdings
The AdvisorShares Pure US Cannabis ETF (MSOS) is an actively managed, non-diversified fund that seeks long-term capital appreciation by investing primarily in U.S. companies deriving at least half of their net revenue from the marijuana and hemp business, along with derivatives such as total return swaps that replicate the economic characteristics of those securities. Launched in September 2020, the fund charges a net expense ratio of approximately 0.78% and holds roughly two dozen underlying positions, with assets under management (AUM) near $800 million.
Because many leading U.S. cannabis operators list on Canadian exchanges or over-the-counter (OTC) markets, MSOS relies heavily on swap contracts to gain exposure. Its largest exposures center on Trulieve Cannabis, Curaleaf, and Green Thumb Industries, supplemented by smaller positions in Glass House Brands, Verano Holdings, Cresco Labs, and TerrAscend. This concentrated structure makes the fund a pure-play proxy for U.S. cannabis MSOs and leaves it highly correlated with federal regulatory headlines and the tax treatment of the sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
MSOS Price Performance: Last 30 Days vs. the Quarter
Over the last 30 days, MSOS fell approximately 25%, from a closing level near $5.18 to about $3.91. The decline was sharp and concentrated in a matter of sessions rather than gradual, punctuated by elevated trading volume during the initial selloff.
The broader three-month picture is more tempered. Over the trailing quarter, MSOS is down roughly 8%, having traded largely within a range between the low $4 area and the low $5 area. A mid-September rally pushed the fund to a multi-month peak near $5.43 before the regulatory setback reversed those gains. This pattern—episodic surges followed by sharp givebacks—has characterized the fund's recent price behavior and underscores its sensitivity to policy-driven sentiment.
What Drove the Recent 30-Day Decline in MSOS
The primary catalyst was a procedural pause in the Drug Enforcement Administration's (DEA) effort to reschedule cannabis from Schedule I to Schedule III. A Government Accountability Office (GAO) report raised questions about the process used to reach the rescheduling proposal, prompting an administrative law judge to temporarily halt the proceedings. That rekindled uncertainty over the timeline for ending Section 280E of the tax code, which currently bars cannabis businesses from deducting ordinary operating expenses and drives effective tax rates well above statutory levels.
Because ending Section 280E is central to the earnings and cash-flow outlook for U.S. MSOs, the pause hit the sector broadly. Trulieve, one of MSOS's largest exposures, fell roughly 14% to 16%, while other operators such as Glass House Brands posted double-digit declines. MSOS's concentration in these names translated those losses directly into the fund's net asset value (NAV), amplifying the move relative to broader equity markets. Consolidation activity, including M&A interest involving Canadian operators, continued in the background but was overshadowed by the regulatory setback.
Quarterly Performance Drivers for MSOS
Over the trailing three months, MSOS's performance has been shaped less by company fundamentals than by shifting expectations around federal cannabis policy. Optimism about rescheduling, potential relief from Section 280E, and the prospect of major U.S. exchange uplistings drove intermittent rallies, while procedural delays and lingering legislative gridlock triggered reversals. Institutional positioning has remained cautious, with the sector still dependent on retail and specialized investors.
The quarter's roughly 8% net decline reflects a market caught between improving underlying operator economics and unresolved regulatory risk. Earnings and free cash flow (FCF) for several large MSOs have improved as operators rationalized costs, but those gains have been repeatedly discounted against the backdrop of policy uncertainty.
MSOS Outlook: Factors to Monitor Going Forward
The most important variable for MSOS remains the trajectory of federal cannabis rescheduling and any legislative action addressing Section 280E. Investors should monitor the rescheduling proceedings, potential reopening of the administrative record, and signals from federal regulators on timing. A shift to Schedule III would meaningfully improve after-tax profitability and cash flow across the fund's holdings.
Beyond policy, attention should focus on the earnings and cash-flow trajectory of Trulieve, Curaleaf, and Green Thumb Industries, particularly their margin trends and capital spending. Progress toward major U.S. exchange uplistings—and the institutional flows and index eligibility that could follow—represents another structural catalyst. Macroeconomic conditions, including interest rates and consumer spending, and persistent competitive pricing pressure within state markets also warrant monitoring. These themes, rather than day-to-day headline moves, are likely to define the fund's direction in the coming months. From what I see, this remains a policy-sensitive name worth tracking closely.
Exploring Tickeron AI Tools in My Research
I often turn to Tickeron’s AI Screener when evaluating thematic ETFs like this one. It lets me scan for technical signals, volatility patterns, and industry peers quickly, helping me cross-check momentum and rotation ideas without sifting through charts manually. The platform has become a regular part of how I refine ideas around volatile sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for MSOS turns negative, indicating new downward trend
MSOS saw its Momentum Indicator move below the 0 level on September 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 75 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for MSOS turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 34 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
MSOS moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MSOS crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MSOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MSOS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MSOS's RSI Indicator exited the oversold zone, 31 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 66 of 67 cases where MSOS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +8.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MSOS advanced for three days, in 195 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
MSOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category MiscellaneousSector
Advertisement